Editorial Policy
Source Hierarchy
Our editorial policy prioritizes high-quality, peer-reviewed sources above all else. At the top of our hierarchy are double-blind, placebo-controlled human clinical trials published in recognized scientific journals. This is followed by robust preclinical animal studies, in-vitro mechanistic data, and finally, historical community observations which are strictly categorized as anecdotal.
Attribution and Linking
We believe in transparent knowledge sharing. Every substantive biological claim on our platform must be accompanied by proper attribution. We actively link out to original literature using Digital Object Identifiers (DOIs), PubMed IDs (PMIDs), or direct open-source repository links to allow readers to evaluate the raw data independently.
Claim Calibration
We actively calibrate our language to prevent overstatement. Theoretical potential must never be presented as established medical fact. When discussing emerging peptide therapies, we use precise conditional language and explicitly state when data is derived solely from animal models or uncontrolled community trials rather than formal human medicine.
Community Reports Treatment
Peptide research often moves faster than formal clinical literature. We include community-reported protocols and outcomes to reflect the current state of public exploration. However, these are strictly segregated and labeled as "Community Insights" or "Educational Composite Scenarios". They are treated as contextual information and must never be interpreted as verified medical advice.